The route to success is often a winding track with unexpected obstacles
Will 2024 be a 'Zeitenwende' moment for the IO field..
Which Thunderbirds are Go in this niche?!
Red and green flags to watch out for in relapsed SCLC
Where is the ADC space heading and waht issues need to be addressed?
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
Where to pivot next? That's the question...
Can bicyclic toxin and radio conjuates do a better job than ADCs and RLTs?
Who's going to be roaring forward?
Are the wheels falling off some of the early stage wagons already?
Five trials with an eye for opening minds in entirely different ways!
Interpreting some of the early trails reading out at ASCO24
When the going gets tough, get wacky...
How to beat imatinib and 2nd Gen TKIs
Teasing out relevant markers and learning more about what patients tumours are telling us is key
It's time to challenge our thinking on cytokines
When resistance and toxicities collide, the inevitable fallout is more likely
What's looking interesting in early stage trials at ASCO24?
Can a new generation of bispecifics change our mind about a particular target?
Switching focus in the critical KRAS pocket
Segueing between preclinical and clinical data
Do not feed the alligators is a common sign seen in the hammock areas of Florida where brackish fresh…
